CTA has delivered strong absolute returns. From inception through 02/28/26, CTA's NAV total cumulative return was 51.52%, translating to an annualized return of 11.01%.

TransMedics continues to reinvent the organ transplant industry, but the market insists the stock is "overvalued" now.

Cherry sodas are a nostalgic, refreshing treat, but they're not created equal. We tried and ranked some popular options to ...

Edenred (EDN:FP) looks undervalued at 8x P/E with a 7% dividend; review cash flow strength, margins, and regulatory risks.

The Nigerian equity market closed February on a softer note, with the All-Share Index settling at 192,826.8 points, slipping below ...

Omatek Ventures Plc filed its unaudited consolidated financial statements for the year ended December 31, 2025, on January 30, 2026. The document covers the full financial year for Nigeria's first ...

Warren Buffett’s final quarter, Greg Abel’s debut. Why earnings fell, insurance cooled, and what $373B cash means.

Despite a 48% Bitcoin drop, ETFs and corporate treasuries keep buying, tightening available supply and shifting market ...

The Phillies play a baseball game on Saturday, their first of many over the next nine months. And while the vibes aren’t as high as they were last year, or the year before, or the year before that, ...